IRIS
BOCCARDO, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 39.976
AS - Asia 3.810
NA - Nord America 1.852
SA - Sud America 305
AF - Africa 64
Continente sconosciuto - Info sul continente non disponibili 1
OC - Oceania 1
Totale 46.009
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 39.289
US - Stati Uniti d'America 1.738
SG - Singapore 1.720
CN - Cina 1.052
VN - Vietnam 533
FR - Francia 324
BR - Brasile 198
BD - Bangladesh 161
HK - Hong Kong 121
FI - Finlandia 114
DE - Germania 66
JP - Giappone 53
AR - Argentina 52
GB - Regno Unito 44
MX - Messico 43
CA - Canada 40
IN - India 28
CH - Svizzera 22
IQ - Iraq 22
ID - Indonesia 18
ES - Italia 16
NL - Olanda 14
RU - Federazione Russa 13
VE - Venezuela 13
PH - Filippine 12
EC - Ecuador 11
IE - Irlanda 11
PL - Polonia 11
ZA - Sudafrica 11
MA - Marocco 10
JM - Giamaica 9
SE - Svezia 9
CR - Costa Rica 8
DZ - Algeria 8
JO - Giordania 8
PE - Perù 8
SA - Arabia Saudita 8
TH - Thailandia 8
UA - Ucraina 8
CO - Colombia 7
PK - Pakistan 7
AZ - Azerbaigian 6
PY - Paraguay 6
CL - Cile 5
KE - Kenya 5
TR - Turchia 5
AL - Albania 4
KZ - Kazakistan 4
LT - Lituania 4
SN - Senegal 4
SY - Repubblica araba siriana 4
UY - Uruguay 4
UZ - Uzbekistan 4
AE - Emirati Arabi Uniti 3
BH - Bahrain 3
DK - Danimarca 3
DO - Repubblica Dominicana 3
ET - Etiopia 3
IR - Iran 3
KR - Corea 3
LB - Libano 3
NP - Nepal 3
RO - Romania 3
RS - Serbia 3
SI - Slovenia 3
AF - Afghanistan, Repubblica islamica di 2
AT - Austria 2
BE - Belgio 2
BW - Botswana 2
CI - Costa d'Avorio 2
EG - Egitto 2
GA - Gabon 2
HN - Honduras 2
KW - Kuwait 2
LV - Lettonia 2
MM - Myanmar 2
MU - Mauritius 2
NI - Nicaragua 2
NO - Norvegia 2
OM - Oman 2
RE - Reunion 2
TN - Tunisia 2
TW - Taiwan 2
AM - Armenia 1
AO - Angola 1
AU - Australia 1
BG - Bulgaria 1
BO - Bolivia 1
BS - Bahamas 1
BY - Bielorussia 1
BZ - Belize 1
CG - Congo 1
CZ - Repubblica Ceca 1
GN - Guinea 1
GR - Grecia 1
GT - Guatemala 1
HR - Croazia 1
IL - Israele 1
ML - Mali 1
MN - Mongolia 1
Totale 45.992
Salva come PNG Salva come JPEG
Città #
Genova 25.260
Genoa 8.191
Rapallo 3.374
Vado Ligure 2.245
Singapore 819
San Jose 611
Lauterbourg 317
Ashburn 207
Ho Chi Minh City 164
Beijing 128
New York 122
Hanoi 121
Helsinki 114
Hong Kong 114
Bordighera 65
Santa Clara 64
Frankfurt am Main 51
Tokyo 44
Council Bluffs 43
Los Angeles 36
Tianjin 27
Mexico City 25
São Paulo 22
Chicago 21
Zurich 20
Haiphong 19
Orem 17
Guangzhou 16
Dallas 15
City of London 13
Biên Hòa 12
Da Nang 12
Rome 12
Buffalo 11
Milan 11
Montreal 11
San Francisco 11
Atlanta 10
Dublin 10
Hải Dương 10
Naples 10
Amsterdam 9
Toronto 9
Cardiff 8
Jakarta 8
Philadelphia 8
Phoenix 8
Rio de Janeiro 8
Seattle 8
Shanghai 8
Stockholm 8
Warsaw 8
Amman 7
Curitiba 7
Madrid 7
Miami 7
Porto Alegre 7
San José 7
Bangkok 6
Boardman 6
Bắc Ninh 6
Can Tho 6
Chennai 6
London 6
Shenzhen 6
Vĩnh Long 6
Baghdad 5
Houston 5
Kingston 5
Mumbai 5
Nuremberg 5
Phủ Lý 5
Quảng Ngãi 5
Thái Nguyên 5
Baku 4
Buenos Aires 4
Charlotte 4
Chengdu 4
Dakar 4
Johannesburg 4
Lanús 4
Las Vegas 4
Long Xuyen 4
Manchester 4
Newark 4
Northbrook 4
Poplar 4
Recife 4
Suzhou 4
Tashkent 4
Verona 4
Volta Redonda 4
Vĩnh Tường 4
Winnipeg 4
Ân Thi 4
Belo Horizonte 3
Bologna 3
Brasília 3
Brooklyn 3
Cagliari 3
Totale 42.724
Salva come PNG Salva come JPEG
Nome #
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years 292
Overexpression of Periostin in Tumor Biopsy Samples Is Associated With Prostate Cancer Phenotype and Clinical Outcome 250
A multi-peptide, dual-adjuvant telomerase vaccine (GX301) is highly immunogenic in patients with prostate and renal cancer 228
Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: Meta-analysis of individual patient data from ten randomised trials 221
Impaired response to influenza vaccine associated with persistent memory B cell depletion in non-Hodgkin's lymphoma patients treated with rituximab-containing regimens. 215
A Case of Advanced Mucinous Adenocarcinoma of Bladder in an Adult Patient Treated With Capecitabine-Based Chemotherapy and Review of Literature 213
Epidemiological Characteristics and Survival in Patients with De Novo Metastatic Prostate Cancer 213
Aromatase inhibitors versus tamoxifen in early breast cancer: Patient-level meta-analysis of the randomised trials 208
A Case of Plasmacytoid Variant of Bladder Cancer with a Single Penile Metastasis and a Complete Response to Carboplatin-Based Chemotherapy and Review of the Literature 205
Adaptive phenotype drives resistance to androgen deprivation therapy in prostate cancer 201
Prospective study to optimize care and improve knowledge on ovarian function and/or fertility preservation in young breast cancer patients: Results of the pilot phase of the PREgnancy and FERtility (PREFER) study 201
Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial. 201
Androgen-deprivation therapy is more than palliation in oligometastatic prostate cancer 199
Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy 193
CDK4/6 inhibitors in advanced hormone receptor-positive/HER2-negative breast cancer: a systematic review and meta-analysis of randomized trials 193
Management of young women with early breast cancer 192
A hnRNP K–AR-related signature reflects progression toward castration-resistant prostate cancer 191
Abiraterone acetate and prednisone in the pre- and post-docetaxel setting for metastatic castration-resistant prostate cancer: A mono-institutional experience focused on cardiovascular events and their impact on clinical outcomes 190
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma 190
Apalutamide treatment and metastasis-free survival in prostate cancer 189
Efficacy of motesanib diphosphate in non-small-cell lung cancer. 185
Telomerase-based GX301 cancer vaccine in patients with metastatic castration-resistant prostate cancer: a randomized phase II trial 185
Very late recurrence of renal cell carcinoma experiencing long-term response to sunitinib: a case report 183
Prognostic variables in localized small cell neuroendocrine carcinoma of the bladder: A population-based study 182
Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials 181
Prognostic value of preoperative serum levels of periostin (PN) in early breast cancer (BCa) 181
Androgen receptor and heterogeneous nuclear ribonucleoprotein K colocalize in the nucleoplasm and are modulated by bicalutamide and 4-hydroxy-tamoxifen in prostatic cancer cell lines. 179
Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survival. 179
Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer 179
Ipilimumab in non-small cell lung cancer and small-cell lung cancer: new knowledge on a new therapeutic strategy. 178
Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials 177
Differential expression of nuclear lamins in normal and cancerous prostate tissues 176
Effects of three cytokine regimens on hematologic recovery and progenitor cell mobilization after high-dose cyclophosphamide, etoposide, and cisplatin. 176
Fibroblast Growth Factor Receptor (FGFR): A New Target for Non-small Cell Lung Cancer Therapy 176
Belagenpumatucel-L for the treatment of non-small cell lung cancer 175
Adjuvant chemotherapy of bladder cancer. 174
Predictors of long-term response to abiraterone in patients with metastastic castration-resistant prostate cancer: a retrospective cohort study 174
Matrix-assisted laser desorption/ionisation (MALDI) TOF analysis identifies serum angiotensin II concentrations as a strong predictor of all-cause and breast cancer (BCa)-specific mortality following breast surgery 174
Targeting androgen-independent pathways: new chances for patients with prostate cancer? 172
The prognostic role of baseline metabolic tumor burden and systemic inflammation biomarkers in metastatic castration-resistant prostate cancer patients treated with Radium-223: A proof of concept study 169
Next Generation Sequencing In Non-Small Cell Lung Cancer: New Avenues Toward The Personalized Medicine. 167
Genitourinary tumours in the targeted therapies era: New advances in clinical practice and future perspectives 167
Uncommon EGFR Exon 19 Mutations Confer Gefitinib Resistance in Advanced Lung Adenocarcinoma 166
Cisplatin (C)-paclitaxel (P) chemotherapy (CT) regimen with concurrent radiotherapy (RT) in local advanced (LACC) or recurrent (LRCC) cervical cancer: 14 year-results of a phase II study 166
May adjuvant therapy play a role for the management of renal cell carcinoma? A review of literature and ongoing trials 166
Combination of sorafenib and weekly gemcitabine in patients (pts) with metastatic renal cell Cancer (MRCC): A phase II study, preliminary results 166
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials 164
Concurrent vs Sequential Adjuvant Chemotherapy and Hormone Therapy in Breast Cancer: A Multicenter Randomized Phase III Trial 164
T-DM1 Efficacy in Patients With HER2-positive Metastatic Breast Cancer Progressing After a Taxane Plus Pertuzumab and Trastuzumab: An Italian Multicenter Observational Study 164
Changes in the expression of cytokeratins and nuclear matrix proteins are correlated with the level of differentiation in human prostate cancer 163
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: An overview of the randomised trials 163
Intracystic epidermal growth factor level is predictive of breast-cancer risk in women with gross cystic disease of the breast 162
Paclitaxel plus organoplatins: still the gold standard in advanced ovarian cancer? 162
Immunotherapy for genitourinary cancer: State of the art and new perspectives 162
A multicenter randomized trial comparing the luteinizing hormone-releasing hormone analogue goserelin acetate alone and with flutamide in the treatment of advanced prostate cancer. The International Prostate Cancer Study Group. 161
Heterogeneous nuclear ribonucleoprotein K: altered pattern of expression associated with diagnosis and prognosis of prostate cancer. 161
68P * Prognostic value of periostin (PN) expression in early breast cancer (BCa): Long-term mortality outcomes 161
Abiraterone or Docetaxel for Castration-sensitive Metastatic Prostate Cancer? That Is the Question! 161
Prognostic value of stromal and epithelial periostin expression in human prostate cancer: correlation with clinical pathological features and the risk of biochemical relapse or death 160
Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer: updated results of a multicentric trial. 160
Bone metastases from prostate cancer: hormonal therapy 160
Time trends in incidence rates and survival of newly diagnosed stage IV breast cancer by tumor histology: a population-based analysis 160
Dose-dense adjuvant chemotherapy in early breast cancer patients: 15-year results of the Phase 3 Mammella InterGruppo (MIG)-1 study 160
Adjuvant therapy for patients with node negative breast cancer. 159
Serum enterolactone levels and mortality outcome in women with early breast cancer: a retrospective cohort study. 159
Prognostic value of nuclear matrix protein expression in localized prostate cancer. 159
Survival prediction in everolimus-treated patients with metastatic renal cell carcinoma incorporating tumor burden response in the RECORD-1 trial. 158
D-TRP-6-LH-RH treatment of advanced prostatic cancer 158
Combinations of hormonal therapy and chemotherapy 158
Alternating chemo-radiotherapy in bladder cancer: a conservative approach. 157
Urethral stricture and scrotal abscess: a rare case presentation of penile cancer and review of the literature 157
Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. 156
Role of Circulating Tumor Cells (CTC), Androgen Receptor Full Length (AR-FL) and Androgen Receptor Splice Variant 7 (AR-V7) in a Prospective Cohort of Castration-Resistant Metastatic Prostate Cancer Patients 156
Ovarian ablation in early breast cancer: overview of the randomised trials. 155
Periostin: A Novel Prognostic and Therapeutic Target For Genitourinary Cancer? 154
Leiomyosarcoma of the broad ligament: a case report and review of literature. 152
Communicating cancer diagnosis and prognosis: when the target is the elderly patient-a GIOGer study. 152
Priming action on progesterone receptor synthesis by estradiol and tamoxifen in the 7,12-dimethylbenz(a)anthracene-induced rat mammary carcinoma. 151
Combined treatment with chemotherapy and radiotherapy in high-risk FIGO stage III-IV endometrial cancer patients. 151
Role of immunotherapy in the treatment of advanced non-small-cell lung cancer. 151
Switching to aromatase inhibitors in early breast cancer. 150
Cardiovascular disease (CVD) markers in patients(pts) with prostate cancer(PCa) treated with GN-RH agonists(AG) or antagonist(AN): a prospective cohort study 150
Long-term endocrine effects of administration of either a non-steroidal antiandrogen or a luteinizing hormone-releasing hormone agonist in men with prostate cancer. 149
Use of metronomic chemotherapy in oncology: results from a national Italian survey. 149
Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study 149
Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial. 149
Potential Mechanisms of Ovarian Protection with Gonadotropin-Releasing Hormone Agonist in Breast Cancer Patients: A Review 149
Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: Long term results of the Italian Tamoxifen Anastrozole trial. 148
Re: j. Alfred witjes. A case of abiraterone acetate withdrawal. Eur urol 2013;64:517-8. 148
Prognostic factors in patients receiving third-line targeted therapy for metastatic renal cell carcinoma. 148
Italian national consensus conference on prostate cancer screening (Florence, May 17, 2003)--final consensus document. 148
Nafarelin acetate and benign prostatic hyperplasia. 147
Relevance of HBV/HBcAb screening in lymphoma patients treated in the Rituximab era 147
Incidental advanced-stage Hodgkin lymphoma diagnosed at the time of radical prostatectomy for prostatic cancer: a case report and review of literature. 147
Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer 147
Estramustine phosphate (estracyt) following androgens in men with refractory stage D2 prostate cancer. 147
A large SEER- based study of survival trends in patients with de novo metastatic prostate cancer 147
Randomized phase III trial of adjuvant epirubicin followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) versus CMF followed by epirubicin in patients with node-negative or 1-3 node-positive rapidly proliferating breast cancer. 146
Oral vinorelbine in the treatment of non-small-cell lung cancer. 146
Influence of bicalutamide with or without tamoxifen or anastrozole on insulin-like growth factor 1 and binding proteins in prostate cancer patients. 146
Totale 17.086
Salva come PNG Salva come JPEG
Categoria #
all - tutte 142.938
article - articoli 128.480
book - libri 673
conference - conferenze 288
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 13.497
Totale 285.876
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021264 0 0 0 0 0 0 0 0 0 0 0 264
2021/20224.214 105 289 202 604 152 290 132 1.154 233 379 96 578
2022/20234.052 409 225 46 383 741 831 7 272 729 30 317 62
2023/20241.832 85 294 46 205 154 317 99 113 84 61 94 280
2024/20255.476 130 458 218 402 719 539 482 884 223 262 470 689
2025/20269.420 1.031 311 661 742 1.274 1.067 1.641 429 603 911 599 151
Totale 46.719